Imatinib Mesylate

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 39, Issue , 2014, Pages 265-297

  Al Hadiya, Badraddin M H ^a   Bakheit, Ahmed H H ^a   Abd Elgalil, Ahmed A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Background; Cancer drug; Clinical Applications; Comprehensive profile; Imatinib mesylate; Interactions; Pharmacology

Indexed keywords

IMATINIB;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG NOMENCLATURE; DRUG RESISTANCE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IONIZATION; MASS SPECTROMETRY; MELTING POINT; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL ROTATION; POTENTIOMETRY; PRIORITY JOURNAL; SPECTROPHOTOMETRY; THERMOGRAVIMETRY; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; WETTABILITY; X RAY POWDER DIFFRACTION;

BACKGROUND; CANCER DRUG; CLINICAL APPLICATIONS; COMPREHENSIVE PROFILE; IMATINIB MESYLATE; INTERACTIONS; PHARMACOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMISTRY, PHARMACEUTICAL; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR STRUCTURE; PIPERAZINES; PYRIMIDINES;

EID: 84899690980     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800173-8.00006-4     Document Type: Chapter

References (54)

1. Gambacorti-Passerini C. Part I: milestones in personalised medicine-imatinib. Lancet Oncol. 2008, 9(6):600.
2. Druker B.J., Lydon N.B. Lessons learned from the development of an ab1 tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Investig. 2000, 105(1):3-8.
3. Martindale: The Complete Drug Reference 2009, 733. Pharmaceutical Press, USA, Frpharms. 36th ed. S.C. Sweetman (Ed.).
4. http://www.Drugbank.Ca/Drugs/Db00619.
5. http://En.Wikipedia.Org/Wiki/Imatinib.
6. Zimmermann J.B., Mett E.H., Meyer T., Lydon N.B. Traxler. Bioorg. Med. Chem. Lett. 1996, 6:1221-1226.
7. http://www.Seqchem.Com/Safetysheet.Php?Sqindex=Srp00530i.
8. Indian Pharmacopoeia, Controller of publications, New Delhi, 2010, p. 1484.
9. Sandhu N.R., Loganathan S.K., Sengodan S.P. Design and evaluation of imatinib mesylate microspheres using chitosan and hpmc k100. Int. J. Pharm. Technol. 2012, Available Online through Research Article http://www.ijptonline.com (0975-766X).
10. O. Loiseleur, D. Kaufmann, S. Abel, H.M. Buerger, M. Meisenbach, B. Schmitz, G.W.O. Sedelmeier, Patent 03/066,613, 2003.
11. A. Kompella, R. Bhujanga, C. Venkaiah, Process for the preparation of the anticancer drug imatinib and its analogues, WO Patent 108,699, 2004.
12. Szakács Z., Béni S., Varga Z., Örfi L., Kéri G., Noszál B. Acid-base profiling of imatinib (gleevec) and its fragments. J. Med. Chem. 2005, 48(1):249-255.
13. A. Huang, L. Xing, L. Zelikovitch, J. Kaspi, U.S. Patent 2,006,149,061, 2006.
14. http://www.Lclabs.Com/Prodfile/G-K/I-5508.Php4.
15. Sandhu N.R., Loganathan S.K., Sengodan S.P. Design and evaluation of imatinib mesylate microspheres using chitosan and hpmc k100. Int. J. Pharm. Technol. 2012, Available online through research article, (0975-766X). http://www.ijptonline.com.
16. S. Jenkins, G. Liversidge, Nanoparticulate imatinib mesylate formulations, WO Patent 2,006,133,046, 2006.
17. R.B. Parthasaradhi, R.K. Rathnakar, R.R. Raji, R.D. Muralidhara, R.K.S. Chander, Polymorphs of imatinib mesylate, U.S. Patent 7,300,938, 2007, Google Patents.
18. K. Amala, T.S. Rao, S. Rachakonda, N.V. Chowdary, K. Podili, Polymorphic form of imatinib mesylate and a process for its preparation, U.S. Patent 8,048,883, 2011.
19. Veverka M., Šimon P., Gallovič J., Jorík V., Veverková E., Dubaj T. Imatinib mesylate cocrystals: synthesis, screening, and preliminary characterization. Monatshefte für Chemie-Chemical Monthly 2012, 143(10):1405-1415.
20. Łaszcz M., Kosmacińska B., Korczak K., Śmigielska B., Glice M., Maruszak W., Groman A., Beczkowicz H., Żelazko Ł. Tudy on compatibility of imatinib mesylate with pharmaceutical excipients. J. Therm. Anal. Calorim. 2007, 88(2):305-310.
21. http://www.Lookchem.Com/Imatinib-Mesylate/.
22. http://www.Guidechem.Com/Dictionary/220127-57-1.html.
23. Bende G., Kollipara S., Sekar V., Saha R. UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies. Pharmazie 2008, 63(9):641-645.
24. Kumar Raja J., Sundar V.D., Magesh A.R., Nandhakumar S., Dhanaraju M.D. Validated spectrophotometric estimation of imatinib mesylate in pure and tablet dosage form. Int. J. Pharm. Technol. 2010, 2(3):490-495.
25. Casida M.E., Casida K.C., Salahub D.R. Excited-state potential energy curves from time-dependent density-functional theory: a cross section of formaldehyde's 1A1 manifold. Int. J. Quant. Chem. 1998, 70(4-5):933-941.
26. Stratmann R.E., Scuseria G.E., Frisch M.J. An efficient implementation of time-dependent density-functional theory for the calculation of excitation energies of large molecules. J. Chem. Phys. 1998, 109:8218.
27. Cances E., Mennucci B., Tomasi J. A new integral equation formalism for the polarizable continuum model: theoretical background and applications to isotropic and anisotropic dielectrics. J. Chem. Phys. 1997, 107:3032.
28. Cossi M., Scalmani G., Rega N., Barone V. New developments in the polarizable continuum model for quantum mechanical and classical calculations on molecules in solution. J. Chem. Phys. 2002, 117:43.
29. Mennucci B., Tomasi J. Continuum solvation models: a new approach to the problem of solute's charge distribution and cavity boundaries. J. Chem. Phys. 1997, 106:5151.
30. Srivastava A., Joshi B., Tandon P., Ayala A., Bansal A., Grillo D. Study of polymorphism in imatinib mesylate: a quantum chemical approach using electronic and vibrational spectra. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2013, 103:325-332.
31. Liu Y.F., Wang C.L., Bai Y.J., Han N., Jiao J.P., Qi X.L. A facile total synthesis of imatinib base and its analogues. Org. Process Res. Dev. 2008, 12(3):490-495.
32. Hopkin M.D., Baxendale I.R., Ley S.V. A flow-based synthesis of Imatinib: the API of Gleevec. Chem. Comm 2010, 46(14):2450-2452.
33. Marull M., Rochat B. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. J. Mass Spectrom. 2006, 41(3):390-404.
34. Hammam E., El-Desoky H., Tawfik A., Ghoneim M. Voltammetric behavior and quantification of the anti-leukemia drug imatinib in bulk form, pharmaceutical formulation, and human serum at a mercury electrode. Can. J. Chem. 2004, 82(7):1203-1209.
35. Gschwind H.P., Pfaar U., Waldmeier F., Zollinger M., Sayer C., Zbinden P., Hayes M., Pokorny R., Seiberling M., Ben-Am M. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos. 2005, 33(10):1503-1512.
36. Ajimura T.O., Borges K.B., Ferreira A.F., De Castro F.A., De Gaitani C.M. Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients. Electrophoresis 2011, 32(14):1885-1892.
37. RodriD́Guez Flores J., Berzas J., Castaneda G., Rodriguez N. Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine. J. Chromatogr. B 2003, 794(2):381-388.
38. Vadera N., Subramanian G., Musmade P. Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form. J. Pharm. Biomed. Anal. 2007, 43(2):722-726.
39. Bakhtiar R., Lohne J., Ramos L., Khemani L., Hayes M., Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2002, 768(2):325-340.
40. Velpandian T., Mathur R., Agarwal N.K., Arora B., Kumar L., Gupta S.K. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J. Chromatogr. B 2004, 804(2):431-434.
41. Ivanovic D., Medenica M., Jancic B., Malenovic A. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules. J. Chromatogr. 2004, B 800(1):253-258.
42. Widmer N., Béguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M., Leyvraz S., Rosselet A., Biollaz J., Decosterd L. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J. Chromatogr. B 2004, 803(2):285-292.
43. Satyanarayana E.R.G., Jitendra Kumar P., Hanumantha Rao K., Sridhar B., Nagaraju P. Development and Validation of New Reversed Phase High Performance Liquid Chromatography Method for the Estimation of Imatinib in Bulk and Pharmaceutical Dosage Forms. Int. J. Res. Pharm. Biomed. Sci. 2010, 1(1):6-9.
44. Miura M., Takahashi N., Sawada K.I. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J. Chromatogr. Sci. 2011, 49(5):412-415.
45. Kuna, Arun Kumar, Kuna Jagadeesh Kumar RP-HPLC method development and validation of imatinib mesylate in tablet dosage form. Int. J. Pharm. Pharm. Sci. 2011, 3(0975-1491):162-165.
46. Teoh M., Narayanan P., Moo K., Radhakrisman S., Pillappan R., Bukhari N., Segarra I. HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice. Pak. J. Pharm. Sci. 2010, 23(1):35-41.
47. Bende G., Kollipara S., Kolachina V., Saha R. Development and validation of an stability indicating RP-LC method for determination of imatinib mesylate. Chromatographia 2007, 66(11):859-866.
48. Nageswari A., Mukkanti K. Stability-indicating UPLC method for determination of imatinib mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J. Pharm. Biomed. Anal. 2012, 66:109-115.
49. Medenica M., Jancic B., Ivanovic D., Malenovic A. Experimental design in reversed-phase high-performance liquid chromatographic analysis of imatinib mesylate and its impurity. J. Chromatogr. A 2004, 1031(1):243-248.
50. Szczepek W., Kosmacińska B., Bielejewska A., Łuniewski W., Skarżyński M., Rozmarynowska D. Identification of imatinib mesylate degradation products obtained under stress conditions. J. Pharm. Biomed. Anal. 2007, 43(5):1682-1691.
51. W.A. Catterall, K. Mackie, Goodman and Gilman's The Pharmacological Basis of Therapeutics, Local Anesthetics (L.L. Brunton, B.A. Chabner, B.C. Knollmann, Eds.), 2011, pp. 1732-1734.
52. Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 2005, 44(9):879-894.
53. Sneed T.B., Kantarjian H.M., Talpaz M., O'brien S., Rios M.B., Bekele B.N., Zhou X., Resta D., Wierda W., Faderl S., Giles F., Cortes J.E. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004, 100(1):116-121.
54. A. Weisman, S. Krlovonos, E. Danon, I. Adin, C. Iustain, Stable amorphous imatinib mesylate and production process therefor, US 2008/0234286 A1, 2008.